Echosens

11/04/2026

An estimated 95 million people worldwide are living with MASLD, yet the vast majority remain undiagnosed.

Primary care providers are on the front lines of metabolic health, playing a critical role in identifying conditions like MASLD earlier and helping patients access the right care at the right time.

Echosens is heading to the American College of Physicians (ACP) Internal Medicine Meeting next week! If you’re attending ACP, we’d love to connect.

📍 Stop by Booth #926 to meet our team and learn how FibroScan® is helping support earlier detection of MASLD in clinical practice.

10/04/2026

Last week at the University Hospital of Pontevedra in Spain, a dedicated liver health initiative successfully delivered 231 liver screenings in a single day.

This initiative was led and implemented by the Digestive Service of Pontevedra Hospital and the IDARA Research Group, as part of a broader program running throughout the first half of 2026, where a different topic related to digestive health is addressed each month.

The most recent session focused on metabolic liver disease, with Prof. Javier Crespo participating as guest speaker.
In the afternoon, a public presentation shared the results of the screenings and highlighted the critical importance of liver health, contributing to raising awareness among the wider community.

👏 We would like to extend a special thank you to Dr. Juan Turnes for his key role in coordinating this initiative, which was instrumental to its success.

🤝 The project was co-funded by AbbVie, Novo Nordisk, Roche and Echosens.

The initiative also received strong local media coverage, with features in several newspapers and on local radio throughout the day.

A great example of how clinically-led initiatives, collaboration and education can make a real impact in public health.

01/04/2026

🎉 Retrouvez notre équipe au congrès de la SFD au Centre des Congrès de Lyon !
Nous sommes présents jusqu’au vendredi 3 avril sur le stand n°30 pour vous présenter nos dernières innovations et réaliser des démonstrations de nos solutions.

📌 Ne manquez pas également notre session en partenariat avec Novo Nordisk :
« MASLD/MASH et DT2 : comment FibroScan® permet d’adapter la stratégie thérapeutique ? »
👉 Présentée par Dr Cyrielle Caussy
📆 Jeudi 2 avril à 15h05
📆 Vendredi 3 avril à 10h35

Nous avons hâte d’échanger avec vous ! À très vite 👋


SFD Paramédicale

30/03/2026

🔥 Ultima possibilità di registrarsi per il clinico di stasera sulla stratificazione del rischio della Colangite Biliare Primativa, tenuto da due esperti internisti: Prof. Umberto Vespasiani Gentilucci, e Dott.ssa Francesca Terracciani.

🔎 La stratificazione del rischio rappresenta oggi uno snodo cruciale nella gestione della Colangite Biliare Primitiva, influenzando in modo determinante le scelte terapeutiche, il monitoraggio e la prognosi.

🩺 Programma
🔹I criteri più aggiornati per la valutazione prognostica
🔹 L’impatto della stratificazione sulle decisioni terapeutiche
🔹La gestione del paziente con fibrosi avanzata
🔹 Casi clinici real-world con messaggi applicabili alla pratica quotidiana
🔹 Sessione interattiva di confronto diretto con gli esperti

📅 Iscriviti per mercoledì:
https://event.on24.com/wcc/r/5263987/4EE5D65A57D92B289244F13EE139F8D6?partnerref=Facebook

27/03/2026

✴️ Last week, our North American National Sales Meeting took place at the Palms Resort & Spa in Miami, Florida.
This year’s theme, “Leadership to Legacy. 25 Years & Counting” celebrated Echosens’ journey and the lasting impact we aim to continue building together.

Our teams engaged in insightful presentations, interactive workshops, and a wonderful Awards Ceremony and Dinner honoring outstanding achievements across the organization.

A great opportunity to align, energize, and continue shaping the future of liver health in metabolic care.

25/03/2026

The congress begins today and runs until March 28 in Vienna.
Come meet our team at booth N°2 to learn about the new generation of FibroScan® devices equipped with Guided VCTE™ technology. Stop by for a scan demonstration!
See you soon!

23/03/2026

💬 “The potential of FibroScan®: it gives you and your patients actionable, quantifiable feedback on steatosis and fibrosis—metrics that reflect liver health, not just the number on the scale. It lets you detect subtle changes, monitor disease progression, and tailor treatment in a personalized way. More importantly, it’s a powerful motivator. When patients see their liver fat drop significantly or their fibrosis score improve, it’s tangible proof that their efforts and/or medication are making a difference. And if the numbers don’t improve, you know it’s time to adjust the plan, not just lean in on more weight loss.” — Martin Grajower, Endocrinologist

💡Check out Dr. Grajower’s full white paper “Unlocking Better Patient Outcomes: Why Liver Health Is the Key to Metabolic Wellness”: https://www.echosens.com/en-us/wp-grajower/

18/03/2026

📺 Siamo lieti di invitarvi al nostro prossimo il 1 aprile alle 17:30 :
“Colangite Biliare Primitiva: focus sulla stratificazione del rischio per un corretto management clinico”, tenuto da due rinomati esperti : Prof. Umberto Vespasiani Gentilucci, e Dott.ssa Francesca Terracciani.

🔎 La stratificazione del rischio rappresenta oggi uno snodo cruciale nella gestione della Colangite Biliare Primitiva, influenzando in modo determinante le scelte terapeutiche, il monitoraggio e la prognosi.

🩺 Programma
🔹I criteri più aggiornati per la valutazione prognostica
🔹 L’impatto della stratificazione sulle decisioni terapeutiche
🔹La gestione del paziente con fibrosi avanzata
🔹 Casi clinici real-world con messaggi applicabili alla pratica quotidiana
🔹 Sessione interattiva di confronto diretto con gli esperti

📅 Rimanete aggiornati circa le ultime novità sulla salute del fegato, registratevi oggi stesso: https://event.on24.com/wcc/r/5263987/4EE5D65A57D92B289244F13EE139F8D6?partnerref=Facebook

17/03/2026

The congress starts tomorrow and runs until March 20th in Roma!
📍Come and meet our team at booth no. 12.
We look forward to sharing the latest product innovations and presenting you Next Generation ® equipped with our Guided VCTE™ technology through our booth scanning demos!

📅 Join us for two hands-on workshops on the 19th at 1:45 p.m. and on the 20th at 1:00 p.m. in the Dell'Architettura Room. There, you’ll be able to learn more and attend a live FibroScan® 630 demonstration.


See you soon!

13/03/2026

🥗 March is National — and it begins with World Obesity Day on March 4.
This month offers an opportunity to raise awareness about how everyday lifestyle habits can support better long‑term health.

This year, we want to shed light on the important connection between obesity and (Metabolic Dysfunction‑Associated Steatotic Liver Disease). Both conditions are closely linked and continue to rise globally, yet some risk factors can be prevented through healthy daily habits.

🌿 Nutrition Month reminds us to take care of ourselves - whether it’s incorporating more balanced meals into our day or finding simple ways to stay active.

Let’s use this month to encourage positive routines and empower people to prioritize their health with confidence. 💪✨

10/03/2026

📰 A new clinical study is now available:
In patients following the Fontan procedure, evidence highlights the strong diagnostic and prognostic value of liver stiffness measurement using VCTE.

In this study, validated cut-off thresholds and a practical algorithm incorporating time elapsed since surgery enable accurate rule-in and rule-out of FALD.

➡️ Liver stiffness measurement by FibroScan also correlated with clinically significant events, supporting its non-invasive role in risk stratification and long-term surveillance in the clinical management of this patient population.

Learn more here 👇
🔸English: https://www.echosens.com/lsm-vcte-post-fontan-patients/
🔸Español: https://www.echosens.com/es/lsm-vcte-pacientes-post-fontan/
🔸Français : https://www.echosens.com/fr/vcte-patients-apres-fontan/
🔸Italiano: https://www.echosens.com/it/lsm-vcte-pazienti-post-fontan/
🔸Deutsch: https://www.echosens.com/de/lsm-vcte-post-fontan-patienten/

06/03/2026

📺 Echosens à l’honneur sur BFM Business
Notre CEO Dominique Legros était récemment l’invité de Pari ETI sur BFM Business, une émission animée par Patrice Begay, pour échanger sur les défis et les succès des entreprises françaises.

Dans cette interview, vous découvrirez :
🔹 Le parcours d’Echosens et le développement de FibroScan®, solution de référence pour le diagnostic non-invasif des maladies du foie
🔹 Notre approche de l’innovation au service des professionnels de santé et des patients
🔹 Notre culture RH, centrée sur le développement des talents et la collaboration
🔹 La place stratégique de l’industrialisation française dans notre modèle et la commercialisation de nos produits au niveau international

🎥 Pour visionner l’interview dans son intégralité :
https://www.bfmtv.com/economie/replay-emissions/pari-eti/video-pari-eti-patrice-begay-recoit-dominique-legros-echosens-camille-vever-vever-et-bastien-valensi-cabaia-04-03_VN-202603040953.html

VIDÉO - Ce mercredi 4 mars, Dominique Legros, directeur général d'Echosens, Camille Vever, présidente-directrice générale de Vever, et Bastien Valensi, fondateur de Cabaïa, étaient les invités dans l'émission Pari ETI présentée par Patrice Bégay. Pari ETI est à voir ou écouter tous le...